A double-blind, placebo-controlled, single and multiple ascending dose phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of CCX507-B in healthy male and female subjects

Trial Profile

A double-blind, placebo-controlled, single and multiple ascending dose phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of CCX507-B in healthy male and female subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs CCX 507 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 22 Oct 2014 Results presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology.
    • 21 Oct 2014 Results published in a ChemoCentryx media release.
    • 28 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top